Showing 4001-4010 of 8584 results for "".
- Positive Phase 2a Data Shown for MC2-32, a Novel HSP90 Inhibitor in HShttps://practicaldermatology.com/news/positive-phase-2a-data-shown-for-mc2-32-a-novel-hsp90-inhibitor-in-hs/2462058/MC2-32 (previously RGRN-305), a first-in-class, oral therapy HSP90 inhibitor, performed well in Hidradenitis Suppurativa (HS), according to Phase 2a results presented during a late-breaking session at the European Academy of Dermatology and Venereology (EADV) Annual Meeting in Berlin.
- AbbVie’s JAK inhibitor RINVOQ "Measures Up" in ADhttps://practicaldermatology.com/news/abbvies-jak-inhibitor-rinvoq-measures-up-in-ad/2462057/New Phase 3 research supports the long-term efficacy and safety of RINVOQ (upadacitinib) in moderate to severe atopic dermatitis (AD), according to data analyses from the Measure Up 1, Measure Up 2, and AD Up studies presented at the European Academy of Dermatology and Venereology (EADV) Congress
- Drs. Jedd D. Wolchok and Lisa Newman Elected to National Academy of Medicinehttps://practicaldermatology.com/news/drs-jedd-d-wolchok-lisa-newman-elected-to-national-academy-of-medicine/2462055/Melanoma specialist Dr. Jedd D. Wolchok, the Meyer Director of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine, in partnership with NewYork-Presbyterian, and Dr. Lisa Newman, chief of the section of breast surgery at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornel
- Protagonist Therapeutics JNJ-2113 Update: IL23-Blocker Advances Into Multiple Clinical Development Programs for PsO, UChttps://practicaldermatology.com/news/jnj-2113-update-il23-blocker-advances-into-multple-clinical-development-programs-for-pso-uc/2462054/Protagonist Therapeutics, Inc. will be eligible to receive $60 million in milestone payments in the fourth quarter for the advancement of JNJ-2113 (formerly known as PN-235) into multiple clinical development programs led by Janssen Biotech, Inc., a Johnson & Johnson company (Janssen), the Co
- Professor Alexander Egeberg Named Head of Global Medical Affairs at Leo Pharmahttps://practicaldermatology.com/news/professor-alexander-egeberg-named-will-head-of-global-medical-affairs-at-leo-pharma/2462050/Professor Alexander Egeberg is LEO Pharma’s new Vice President, Head of Global Medical Affairs. The announcement was made ahead of the upcoming 32nd European Academy of Dermatology and Venereology (EADV) Congress. Alexander Egeberg joins LEO Pharma from his role as professor of de
- NPF Update: Group Hosts 25th Dermatology Residents’ Meeting and Research Symposium: A Cure for Allhttps://practicaldermatology.com/news/npf-update-group-hosts-25th-dermatology-residents-meeting-and-research-symposium-a-cure-for-all/2462049/The National Psoriasis Foundation (NPF) celebrated the 25th anniversary of the annual Dermatology Residents’ Meeting on October 7 and 8, 2023 in Washington, D.C. Experts and co-chairs Brad P. Glick, DO, MPH, FAAD, and Samuel Hwang MD, PhD. hosted the silver anniversary event with
- DecisionDx-Melanoma Outperforms MSKCC Nomogram in Predicting Sentinel Lymph Node Positivity in Melanomahttps://practicaldermatology.com/news/decisiondx-melanoma-outperforms-mskcc-nomogram-in-predicting-sentinel-lymph-node-positivity-in-melanoma/2462044/Castle Biosciences, Inc.’s DecisionDx-Melanoma outperformed a nomogram developed at the Memorial Sloan Kettering Cancer Center (MSKCC) in predicting the risk of sentinel lymph node (SLN) positivity in patients with cutaneous melanoma (CM), according to a new study in
- Dermavant Appoints John Darden as New Head of Marketinghttps://practicaldermatology.com/news/dermavant-appoints-john-darden-as-new-head-of-marketing/2462043/John Darden is the new Vice President of Marketing at Dermavant Sciences. In his most recent role as Executive Director, Marketing and U.S. Brand Lead, Mr. Darden directed the healthcare professional, consumer, and field-based marketing strategies for Otezla (apremilast) tablet.
- When Lightning Strikes: A Case Study of Staphylococcal Scalded Skin Syndrome in a 55-year-old Manhttps://practicaldermatology.com/news/when-lightning-strikes-a-case-study-of-staphylococcal-scalded-skin-syndrome-in-a-55-year-old-man/2462042/Five months after being struck by lightning, a 55-year-old male presented with a 2-day history of an erythematous rash. The patient noted his skin had been excessively dry since the lightning strike, and he recently added a new essential oil to his bath. His medical history includes liver failure
- Regenerative Medicine Breakthrough: Researchers Create BioPrinted Full Thickness Skinhttps://practicaldermatology.com/news/regenerative-medicine-breakthrough-researchers-create-bioprinted-full-thickness-skin/2462041/New bioprinted skin may accelerate wound healing, support healthy extracellular matrix remodeling, and aid in complete wound recovery, according to research out of the Wake Forest Institute for Regenerative Medicine (WFIRM). Available grafts are often temporary, or if permanent, h